A Wuxi Biologics unit plans to boost as much as 3.68 billion Hong Kong {dollars} (US$470.5 million) by means of an preliminary public providing in considered one of Asia’s greatest inventory markets.
Wuxi XDC Cayman, a contract growth and manufacturing group targeted on antibody-drug conjugates, is planning to promote 178.45 million shares within the IPO, Wuxi XDC stated.
Copyright ©2023 Dow Jones & Firm, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8